NASDAQ:SYRS Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 02:53 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About Syros Pharmaceuticals Stock (NASDAQ:SYRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Syros Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0120Volume9,653 shsAverage Volume15,104 shsMarket Capitalization$2.68 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Syros Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines that influence gene expression—the processes that control how genes are turned on or off. The company was founded in 2012 and is based in Cambridge, Massachusetts. Its drug-development work has focused primarily on cancer and blood disorders. Syros has advanced tamibarotene, a selective retinoic acid receptor alpha agonist investigated for certain forms of acute myeloid leukemia and myelodysplastic syndrome. Its research portfolio has also included other small-molecule candidates for hematologic cancers and solid tumors. Syros has used genomic and molecular research to identify disease-related patterns of gene activity and guide the development of potential treatments. Its programs have been investigational; the company’s candidates should not be described as approved therapies.AI Generated. May Contain Errors. Read More Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYRS Stock News HeadlinesSyros Announces Pricing of $75.6 Million Public Offering of Common StockJuly 14, 2026 | businesswire.comRege Nephro buys Tamibarotene-related assets from Syros PharmaceuticalsApril 15, 2025 | msn.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 18 at 1:00 AM | Profits Run (Ad)Syros Pharmaceuticals trading resumesMarch 1, 2025 | markets.businessinsider.comSyros Pharmaceuticals Plans to Wind Down OperationsMarch 1, 2025 | marketwatch.comSyros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stockMarch 1, 2025 | markets.businessinsider.comSyros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationFebruary 28, 2025 | businesswire.comSyros Pharmaceuticals stock hits 52-week low at $0.18 amid steep declineJanuary 29, 2025 | msn.comSee More Headlines SYRS Stock Analysis - Frequently Asked Questions How have SYRS shares performed this year? Syros Pharmaceuticals' stock was trading at $0.0004 at the beginning of the year. Since then, SYRS shares have decreased by 75.0% and is now trading at $0.0001. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings data on Thursday, October, 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. Read the conference call transcript. When did Syros Pharmaceuticals' stock split? Shares of Syros Pharmaceuticals reverse split before market open on Monday, September 19th 2022.The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Syros Pharmaceuticals IPO? Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syros Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), Abeona Therapeutics (ABEO) and Sangamo Therapeutics (SGMO). Company Calendar Today11/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SYRS CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees68Year Founded2012Profitability EPS (Trailing Twelve Months)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$164.57 million Net MarginsN/A Pretax Margin-25,275.20% Return on Equity-3,369.56% Return on Assets-97.04% Debt Debt-to-Equity RatioN/A Current Ratio2.25 Quick Ratio2.25 Sales & Book Value Annual Sales$386 thousand Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book0.00Miscellaneous Outstanding Shares26,832,000Free Float23,542,000Market Cap$2.68 thousand OptionableNo Data Beta1.31 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:SYRS) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.